FindTrial
Sign In

Role of Fluorescein dye in patients with brain tumor surgery.

Role of Intraoperative Fluorescein Sodium in resection of Intracranial High-Grade Gliomas. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/077180
Enrollment
40
Registered
2024-11-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

RAHUL SAIKIA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients whose imaging shows features of high-grade gliomas. 2. Patients with high-grade gliomas where complete resection is planned pre-operatively.

Exclusion criteria

Exclusion criteria: 1. Patients with high-grade gliomas where complete resection is not planned (e.g. tumors in the eloquent areas, brainstem, thalamus, basal ganglia). 2. Patients who are unfit for surgery. 3. Histological diagnosis other than glioma. 4. Patients not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study is the residual tumor volume following resection in the fluorescein and non-fluorescein group.Timepoint: Post-operative contrast MRI will be done within 48 hours of resection to check for residual tumor volume.—

Secondary

MeasureTime frame
The secondary outcome of the study is the quality of life of the patients following surgery.Timepoint: Patients will be followed up for a period of 3 months.—

Countries

India

Contacts

Public ContactDEBARSHI CHATTERJEE

Institute of Neurosciences, Kolkata

dc_chatto@hotmail.com8872741184

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026